T2 PI25 ISCIII

About the Group

The Oncogenesis and Antitumor Drugs group is a multidisciplinary team whose research aimed to develop and biologically validate new targeted nanomedicine to treat cancer. The main research lines in the lab are:

• Development of novel animal models of disseminated disease in solid tumours and haematological neoplasms for the mechanistic study of metastases and preclinical drug development.
• Identification of prognostic biomarkers in head and neck squamous cell carcinoma and their functional validation in vivo.
• Development of nanoconjugates for targeted delivery of antitumour drugs or toxins to metastasis stem cells. The Group is within the Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB- Sant Pau), which has been accredited as a Health Research Institute by the Health Institute Carlos III (ISCIII) and as a CERCA Center by the Generalitat of Catalonia. Additionally, the group is part of the Network Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine of the Health Institute Carlos III (CIBER-BBN, CB06/01/1031) and has been recognized as a Consolidated Research Group by the Generalitat of Catalonia since 2005 (2021SGR-01140).

Essential requirements

• Minimum qualification: Bachelor’s degree in Biochemistry, Biotechnology, or a related field
• Oral and written proficiency in Catalonia’s two official languages (Catalan and Spanish), or, if not currently met, the successful candidate must demonstrate— or commit to obtaining within a maximum of one year—an adequate command of both
• Intermediate level of English (written and spoken)
• Intermediate proficiency in standard office software (Excel, Word, PowerPoint, etc.) Skills will be valued
• MSc degree in Molecular Biology, Biomedicine, or a related field
• Completed laboratory animal experimentation course (functions A, B and C)"
• Proven experience in mammalian cell culture
• Experience with proteomics workflows and/or data analysis
• Experience with molecular biology techniques (western blotting, PCR/qPCR, ELISA, cloning)
• Experience with statistical software (GraphPad Prism, SPSS, R)
• Track record of scientific output (peer-reviewed publications and/or conference poster presentations)

Functions

• The successful candidate will provide technical support to the project “Dissecting the cellular crosstalk of PDGFRβ+ cancer-associated fibroblasts as a tool to modulate therapeutic response in microsatellite-stable (MSS) colorectal cancer.” Responsibilities will include, but will not be limited to:
• Subcutaneous and orthotopic implantation of colorectal cancer cells in mice; drug administration; monitoring of tumor progression; tissue collection/harvesting
• Cell line maintenance; tumor dissociation; western blotting; qPCR
• Sample preparation for proteomics studies (cells and tissues)
• Maintaining accurate and complete laboratory records
• Preparation of solutions and routine laboratory reagents Offered
• Contract linked to the PROJECT Dissecting the cellular crosstalk of PDGFR+ cancer-associated fibroblasts as a tool to modulate the therapeutic response in microsatellite stable colorectal cancer.
• Full-time position (37,5h/week; annual workload: of 1.627,50h)
• Remuneration in accordance with ISCIII salary tables
• Research group: Oncogenesis and Antitumor Drug Group Documentation and deadline for submission Interested parties should preferably deliver the documentation (1) in PDF, by e-mail to the Management of the Santa Creu i Sant Pau Hospital Research Institute Foundation, address ir_seleccio@santpau.cat , indicating the reference 2026/034: (1) Application letter and updated Curriculum Vitae At the request of the Santa Creu i Sant Pau Hospital Research Institute Foundation, the candidates must present the documentation accrediting the merits mentioned in the curriculum vitae.